IL6 and neoplasm: Inflammatory mediators such as proinflammatory cytokines (e.g., interleukin‐6 IL‐6]) and catabolic factors (e.g., glucocorticoids), either derived from tumour‐immune system crosstalk or produced by the tumour itself, activate proteolytic systems and blunt protein synthesis, causing muscle wasting.1